Evvy Raised $40 Million in Series B Funding
The New York-based biotech firm secured capital to expand its vaginal health diagnostic platform.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you believe personalized diagnostic testing will improve the standard of care for women's health?
Evvy has secured $40 million in a Series B funding round led by Catalio Capital Management. This investment brings the company's total equity raised to $60 million as it prepares to scale its diagnostic technology.
Why it matters
The capital provides crucial runway for the company to validate new diagnostic models for women's health. It supports the firm's broader strategy to integrate its platform into clinical systems and expand into fertility diagnostics.
Evvy utilizes a CLIA-certified and NYS CLEP-approved metagenomic test that identifies 700+ bacteria and fungi. The platform has already supported over 100,000 patients and 3,000 practitioners through at-home swabbing processes.
The players
Evvy
This New York-based biotech company specializes in vaginal microbiome testing and diagnostic solutions.
Catalio Capital Management
This investment firm acted as the lead investor for the recent Series B funding round.
The details
Patients perform an at-home vaginal swab which is then processed to provide molecular insights reviewed by licensed clinicians. The company relies on 15+ peer-reviewed publications and a dataset of vaginal microbiomes to support its diagnostic methodology.
Timeline
1993 marked the year clinical trials began requiring female participants.
Evvy plans to validate AI-powered diagnostic models over the next six months.
The Tech Race
Evvy's expansion into data-driven women's health diagnostics signals a shift toward addressing historical underrepresentation in medical research. This development positions the firm against legacy diagnostic providers by utilizing specialized metagenomic sequencing to bridge significant gaps in female health data.
Patients may gain improved access to vaginal health testing as the company expands its network through physicians and health systems. The ongoing research could lead to more precise, clinician-reviewed treatments for conditions such as bacterial vaginosis.
The takeaway
The company’s ability to leverage molecular data represents a significant step toward personalized medicine for underserved health conditions. Patients should consult with healthcare providers about how emerging diagnostic tests can fit into their existing personal health routines.
Further reading
For more on the industry's evolution, visit Biotech.
Source note: This article includes information reported by AlleyWatch.
Live Poll
Do you believe personalized diagnostic testing will improve the standard of care for women's health?
